These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25969368)

  • 1. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.
    Fallet V; Saffroy R; Girard N; Mazieres J; Lantuejoul S; Vieira T; Rouquette I; Thivolet-Bejui F; Ung M; Poulot V; Schlick L; Moro-Sibilot D; Antoine M; Cadranel J; Lemoine A; Wislez M
    Ann Oncol; 2015 Aug; 26(8):1748-53. PubMed ID: 25969368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
    Liang X; Li Q; Xu B; Hu S; Wang Q; Li Y; Zong Y; Zhang S; Li C
    Int J Clin Oncol; 2019 Sep; 24(9):1061-1068. PubMed ID: 31065835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
    Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
    J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
    Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
    Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.
    Italiano A; Cortot AB; Ilie M; Martel-Planche G; Fabas T; Pop D; Mouroux J; Hofman V; Hofman P; Pedeutour F
    Int J Cancer; 2009 Nov; 125(10):2479-82. PubMed ID: 19681124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
    Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
    Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies
    Ding Y; Shao Y; Na C; Yin JC; Hua H; Tao R; Jiang Y; Hu R; He X; Miao C; Zhu D; Zhang Z
    J Med Genet; 2022 Jan; 59(1):10-17. PubMed ID: 33115932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.
    Quinn AM; Hickson N; Adaway M; Priest L; Jaeger E; Udar N; Keeling C; Kamieniorz M; Dive C; Wallace A; Byers RJ; Newman WG; Nonaka D; Blackhall FH
    J Thorac Oncol; 2015 May; 10(5):784-792. PubMed ID: 25634010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis.
    Holst VA; Finkelstein S; Colby TV; Myers JL; Yousem SA
    Am J Surg Pathol; 1997 Jul; 21(7):801-11. PubMed ID: 9236836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.